Creades AB
0QI9.L
London Stock Exchange81.15
SEK
-0.50
- -
Creades AB
0QI9.L
(London Stock Exchange)
Recent
price
81.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Creades AB (publ) (STO: CRED A) serves as a long-term, engaged investment company that acquires and develops small and medium-sized listed and unlisted companies with potential for revaluation and value creation through operational, structural, or financial initiatives; its portfolio comprises 60-70% listed holdings including its largest position in Avanza Bank Holding AB, 20-30% unlisted holdings such as Apotea AB, Inet AB, Instabee AB, Mentimeter AB, and StickerApp Inc., and approximately 10% in liquid funds and other assets; the firm typically invests SEK 50-500 million in Swedish-focused opportunities across sectors like technology, healthcare, consumer goods, and digital services, taking minority or majority stakes with board representation where applicable. Founded in 2011 as a spin-off from Investment AB Öresund (publ) and headquartered at Ingmar Bergmans gata 4 in Stockholm, Sweden, Creades operates primarily in the Nordic region with a concentrated portfolio emphasizing active ownership to generate shareholder value, having delivered an 18% annualized return since inception versus the SIX Return Index of 14%. It maintains a wholly-owned listed acquisition vehicle, Creaspac AB, for special purpose acquisition opportunities. Recent developments include the February 2025 completion of a minority investment acquiring 20% of shares in Finnish beauty company Lumene Group from Verdane, enhancing exposure to sustainable beauty products encompassing skincare, makeup, hair care under brands LUMENE, CUTRIN, and IDA WARG; a June 2025 consortium investment with Bure Equity AB and others securing 54.8% ownership in Silex Microsystems AB following an initial 48.2% acquisition; the finalization of Stabelo sale; and a June 2025 partial divestment of approximately 8.8 million shares in Apotea Publ AB alongside Neudi Kapital and others.